Message from the President
Since its founding in 1907, the Kirin Group has been refining its expertise in fermentation and biotechnology for over a century through its original beer business. Today, the Group operates businesses in Alcoholic/Non-alcoholic Beverages, Pharmaceuticals, and Health Science.
In this rapidly changing era, to ensure the company's survival and achieve sustainable growth, we have established Creating Shared Value (CSV) as a core pillar of our management philosophy. This involves addressing social issues using the Group's strengths to create economic value. Under our Long-Term Management Vision, Kirin Group Vision 2027 (KV2027), we aim to maximize corporate value by “becoming a global leader of CSV, creating value across our world of Food & Beverages to Pharmaceuticals.”
In the Alcoholic/Non-alcoholic Beverages business, we are enhancing the brand power of our products based on the principles of consumer-first approach and steady focus on quality that we have inherited since our founding, and delivering joy of connection with people and society. In the Pharmaceuticals business, which we entered by leveraging the fermentation and biotechnology expertise cultivated in the beer business, we are working to create life-changing value that brings smiles to people facing illness as a global specialty pharmaceuticals company originating in Japan. In our Health Science business, we combine Kirin's technologies centered on fermentation and biotechnology with the strengths of FANCL and Australia’s Blackmores, which have joined our group, to deliver health and smiles to more consumers and become one of the largest health science companies in Asia-Pacific.
Through these businesses, Kirin Group aims to be the most trusted company in the world, supporting consumers at every stage of their lives and making them feel glad that Kirin is there for them. To achieve this, we recognize the importance of creating new value that is meaningful to society through human capital and organizational transformation. Therefore, we will focus on enhancing four organizational capabilities.
-
The first is human capital. In particular, we will enhance our investment in human capital of the Health Science business, which is in a stage of accelerated growth, so that it will evolve into a globally competitive organization. We will change our human resources system into one that encourages employees to take on new challenges and take action-first attitudes. We will actively invest in developing strong individuals who improve their expertise and can compete globally and strong teams rich in diversity.
-
The second is research and development. We take pride in our long history of innovation based on advanced technology. However, we will not rest on our laurels, but will further hone our ability to generate ideas for innovative technology and translate them into actual business.
-
Third is DX (digital transformation). We have newly formulated KIRIN Digital Vision 2035 to promote the creation of value and productivity improvements through greater utilization of digital technology. As top management, I will lead DX efforts to further enhance our contribution to our consumers and society.
-
The fourth is marketing. We will develop our knowledge and expertise in brand business, centered on Alcoholic/Non-alcoholic Beverages business, to a higher level with a focus on consumers, and at the same time, we will leverage these strengths in our Health Science business. By deeply understanding consumer needs, we will evolve into a group that continuously delivers innovations that exceed consumer expectations.
The Kirin Group will continue to refine its execution capabilities through the integration of management and the front lines (Genba).
We will continue to engage in dialogue with external stakeholders and promote management that earns their empathy and support. We sincerely request your continued understanding and support.
President & COO,
Kirin Holdings Company, Limited